Healthcare >> Analyst Interviews >> October 5, 2018

Clinical Trial Readouts on the Horizon for NASH Monotherapies

Seedhouse, Steven
Steven Seedhouse, Ph.D., is Vice President, Equity Research, Biotechnology at Raymond James Financial, Inc. Dr. Seedhouse has been a biotech equity research analyst or an associate at various firms since 2015. He joined Raymond James in March 2018. Prior to his career in equity research, Dr. Seedhouse completed a Ph.D. in pharmacology from Roswell Park Cancer Institute in Buffalo, New York, and holds an M.S. in medicinal chemistry from SUNY Buffalo. Profile
Word count: 4,014

TWST: Can you describe what your universe of coverage is at this time?

Dr. Seedhouse: I cover 11 companies in total currently. One of them is